Combination with MEK inhibitors enhances the inhibitory effect on KRAS-mutant tumors, while co-administration with YAP inhibitors synergistically inhibits tumor metastasis; in tumors with abnormal activation of the PI3K/AKT pathway, RASSF4 overexpression enhances the efficacy of PI3K inhibitors [27,28,49]. Here, KRAS is linked to neoplasm.